A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

被引：0

作者：

Ahluwalia, Manmeet ^{[1
,2
]}

Ciesielski, Michael ^{[3
]}

Abad, Ajay ^{[4
]}

Reardon, David ^{[5
,6
]}

Ozair, Ahmad ^{[1
]}

Khosla, Atulya ^{[1
]}

Aiken, Robert ^{[7
]}

Barbaro, Marissa ^{[8
]}

Sinicrope, Kaylyn ^{[9
]}

Peereboom, David ^{[10
]}

Odia, Yazmin ^{[1
]}

Brenner, Andrew ^{[11
]}

Venur, Vyshak ^{[12
,13
]}

Belal, Ahmed ^{[4
]}

Qiu, Jingxin ^{[4
]}

Schilero, Cathy ^{[10
]}

Casucci, Danielle ^{[3
]}

Mechtler, Laszlo ^{[4
,14
]}

Fenstermaker, Robert ^{[4
]}

机构：

[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA

[2] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL USA

[3] Mimivax, Buffalo, NY USA

[4] Rosswell Park Comprehens Canc Ctr, Nokomis, NY USA

[5] Dana Farber Canc Inst, Stoughton, MA USA

[6] Harvard Med Sch, Dept Med, Boston, MA 02115 USA

[7] Atlantic Healthcare, Gerald J Glasser Brain Tumor Ctr, Summit, NJ USA

[8] NYU Langone Med Ctr, New York, NY USA

[9] Norton Brain Tumor Ctr, Loiusville, KY USA

[10] Cleveland Clin, Cleveland, OH USA

[11] UT Hlth San Antonio MD Anderson Canc Ctr, San Antonio, TX USA

[12] Fred Hutchinson Canc Ctr, Sunnyside, WA USA

[13] Univ Washington, Sch Med, Seattle, WA USA

[14] Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

来源：

NEURO-ONCOLOGY | 2024年 / 26卷

关键词：

D O I：

10.1093/neuonc/noae165.1080

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

RTID-04.

引用

页数：1

共 50 条

[1] A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).
Ahluwalia, Manmeet Singh
Ciesielski, Michael J.
Reardon, David A.
Butowski, Nicholas A.
Aiken, Robert
Venur, Vyshak
Abad, Ajay Prakash
Mechtler, Laszlo
Peereboom, David M.
Odia, Yazmin
Sinicrope, Kaylyn
Boockvar, John A.
Brenner, Andrew J.
Barbaro, Marissa
Ozair, Ahmad
Belal, Ahmed
Qiu, Jing-Xin
Khosla, Atulya Aman
Casucci, Danielle M.
Fenstermaker, Robert Alan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
Ahluwalia, M. S.
Ciesielski, M.
Abad, A.
Reardon, D.
Aiken, R.
Barbaro, M.
Sinicrope, K.
Peereboom, D. M.
Odia, Y.
Brenner, A.
Venur, V.
Butowski, N.
Belal, A.
Qiu, J.
Ozair, A.
Khosla, A. A.
Schilero, C.
Figel, S.
Casucci, D.
Mechtler, L.
Fenstermaker, R.
NEURO-ONCOLOGY, 2023, 25
[3] PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)
Ahluwalia, Manmeet
Ciesielski, Michael J.
Abad, Ajay
Reardon, David A.
Aiken, Robert
Barbaro, Marissa
Sinicrope, Kaylyn
Peereboom, David
Odia, Yazmin
Brenner, Andrew
Venur, Vyshak
Belal, Ahmed
Qiu, Jingxin
Khosla, Atulya
Schilero, Cathy
Casucci, Danielle
Mechtler, Laszlo
Fenstermaker, Robert
NEURO-ONCOLOGY, 2022, 24 : 64 - 64
[4] PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Reardon, David
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle
Mechtler, Laszlo
Uhlmann, Erik
Ciesielski, Michael
Fenstermaker, Robert
NEURO-ONCOLOGY, 2018, 20 : 10 - 11
[5] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Ciesielski, Michael J.
Reardon, David A.
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Figel, Sheila
Hutson, Alan
Groman, Adrienne
Withers, Henry
Liu, Song
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Khosla, Atulya
Casucci, Danielle
Mechtler, Laszlo
Fenstermaker, Robert
NEURO-ONCOLOGY, 2022, 24 : 66 - 66
[6] Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
Ahluwalia, Manmeet S.
Reardon, David A.
Abad, Ajay P.
Curry, William T.
Wong, Eric T.
Figel, Sheila A.
Mechtler, Laszlo L.
Peereboom, David M.
Hutson, Alan D.
Withers, Henry G.
Liu, Song
Belal, Ahmed N.
Qiu, Jingxin
Mogensen, Kathleen M.
Dharma, Sanam S.
Dhawan, Andrew
Birkemeier, Meaghan T.
Casucci, Danielle M.
Ciesielski, Michael J.
Fenstermaker, Robert A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (07) : 1453 - +
[7] Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma
Ly, Ina
Richardson, Leland
Liu, Mofei
Muzikansky, Alona
Lou, Kevin
Reardon, David A.
Arrillaga-Romany, Isabel
Forst, Deborah Anne
Jordan, Justin T.
Lee, Eudocia Quant
Dietrich, Jorg
Nayak, Lakshmi
Wen, Patrick Y.
Chukwueke, Ugonma Nnenna
Giobbie-Hurder, Anita
Choi, Bryan D.
Batchelor, Tracy
Kalpathy-Cramer, Jayashree
Curry, William T.
Gerstner, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] JCOG0911 INTEGRA TRIAL: A RANDOMIZED SCREENING PHASE II TRIAL OF CHEMORADIOTHERAPY WITH INTERFERONβ PLUS TEMOZOLOMIDE VERSUS CHEMORADIOTHERAPY WITH TEMOZOLOMIDE ALONE FOR NEWLY-DIAGNOSED GLIOBLASTOMA
Wakabayashi, Toshihiko
Natsume, Atsushi
Mizusawa, Junki
Katayama, Hiroshi
Fukuda, Haruhiko
Shibui, Soichiro
NEURO-ONCOLOGY, 2014, 16
[9] PRELIMINARY DATA FROM A MULTICENTER, PHASE II, RANDOMIZED, NONCOMPARATIVE CLINICAL TRIAL OF RADIATION THERAPY AND TEMOZOLOMIDE WITH OR WITHOUT VANDETANIB IN NEWLY-DIAGNOSED GLIOBLASTOMA
Lee, Eudocia Quant
Batchelor, Tracy T.
Lassman, Andrew B.
Schiff, David S.
Kaley, Thomas J.
Wong, Eric T.
Mikkelsen, Tom
Purow, Benjamin W.
Drappatz, Jan
Norden, Andrew D.
Beroukhim, Rameen
Weiss, Stephanie
Alexander, Brian M.
Sceppa, Christine
Gerard, Mary
Hallisey, Stephen D.
Bochacki, Caelainn A.
Smith, Katrina H.
Muzikansky, Alona M.
Wen, Patrick Y.
NEURO-ONCOLOGY, 2011, 13 : 86 - 86
[10] SAFETY ANALYSIS OF RANDOMIZED BELGIAN PHASE II TRIAL OF EXTENDED USE OF ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
Renard, L.
Clement, P. M.
Hammouch, F.
Boterberg, T.
Verschaeve, V.
Whenham, N.
Mitine, C.
Devriendt, D.
Baurain, J.
NEURO-ONCOLOGY, 2010, 12 : 46 - 47

← 1 2 3 4 5 →